These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2292201)

  • 21. Relationships between renal function and disposition of oral ciprofloxacin.
    Forrest A; Weir M; Plaisance KI; Drusano GL; Leslie J; Standiford HC
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1537-40. PubMed ID: 3190182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of dirithromycin in patients with mild or moderate cirrhosis.
    Mazzei T; Surrenti C; Novelli A; Biagini MR; Fallani S; Cassetta MI; Conti S; Surrenti E
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1556-9. PubMed ID: 10390202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of renal failure on ciprofloxacin pharmacokinetics in rats.
    Nouaille-Degorce B; Veau C; Dautrey S; Tod M; Laouari D; Carbon C; Farinotti R
    Antimicrob Agents Chemother; 1998 Feb; 42(2):289-92. PubMed ID: 9527774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of renal function on the bioavailability of ciprofloxacin.
    Plaisance KI; Drusano GL; Forrest A; Weir MR; Standiford HC
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1031-4. PubMed ID: 2393263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kidney function.
    Webb DB; Roberts DE; Williams JD; Asscher AW
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():83-7. PubMed ID: 3804907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative bioequivalence and pharmacokinetics of ciprofloxacin in healthy male subjects.
    Khan MK; Khan MF
    Pak J Pharm Sci; 2009 Jan; 22(1):1-7. PubMed ID: 19168412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transintestinal elimination of ciprofloxacin.
    Rohwedder RW; Bergan T; Thorsteinsson SB; Scholl H
    Diagn Microbiol Infect Dis; 1990; 13(2):127-33. PubMed ID: 2369809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacokinetics of ciprofloxacin injection in healthy volunteers].
    Hong Z; Wang Y; Xu N; Zhang H; Liang D
    Hua Xi Yi Ke Da Xue Xue Bao; 1995 Sep; 26(3):315-8. PubMed ID: 8586400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-ranging pharmacokinetic study of ciprofloxacin after 200-, 300-, and 400-mg intravenous doses.
    Nix DE; Spivey JM; Norman A; Schentag JJ
    Ann Pharmacother; 1992 Jan; 26(1):8-10. PubMed ID: 1606348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of bioequivalence of ciprofloxacin in healthy male subjects using HPLC.
    Khan MK; Khan MF
    Pak J Pharm Sci; 2008 Jul; 21(3):299-306. PubMed ID: 18614429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function.
    Gasser TC; Ebert SC; Graversen PH; Madsen PO
    Antimicrob Agents Chemother; 1987 May; 31(5):709-12. PubMed ID: 3300537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pharmacokinetics of ciprofloxacin in patients with impaired renal function.
    Boelaert J; Valcke Y; Schurgers M; Daneels R; Rosseneu M; Rosseel MT; Bogaert MG
    J Antimicrob Chemother; 1985 Jul; 16(1):87-93. PubMed ID: 2931415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid.
    Landersdorfer CB; Kirkpatrick CM; Kinzig M; Bulitta JB; Holzgrabe U; Jaehde U; Reiter A; Naber KG; Rodamer M; Sörgel F
    Br J Clin Pharmacol; 2010 Feb; 69(2):167-78. PubMed ID: 20233180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of haemodialysis on the pharmacokinetics of ciprofloxacin.
    Samsom JP
    Pharm Weekbl Sci; 1987 Dec; 9 Suppl():S23-5. PubMed ID: 3438149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in cirrhosis of the liver.
    Höffken G; Lode H; Koeppe P; Ruhnke M; Borner K
    Chemotherapy; 1984; 30(1):7-17. PubMed ID: 6319092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of age on the pharmacokinetics of ciprofloxacin.
    Nilsson-Ehle I; Ljungberg B
    Scand J Infect Dis Suppl; 1989; 60():23-7. PubMed ID: 2756350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disposition kinetics and urinary excretion of ciprofloxacin in goats following single intravenous administration.
    Raina R; Prawez S; Dimitrova DJ; Pankaj NK; Verma PK
    J Vet Sci; 2008 Sep; 9(3):241-5. PubMed ID: 18716443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans.
    Chen L; Greenberg WM; Brand-Schieber E; Wangsa J; Periclou A; Ghahramani P
    Drug Des Devel Ther; 2015; 9():3293-300. PubMed ID: 26150701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses.
    Bergan T; Thorsteinsson SB; Solberg R; Bjornskau L; Kolstad IM; Johnsen S
    Am J Med; 1987 Apr; 82(4A):97-102. PubMed ID: 3578334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.